"Pathologic complete response" trang 1 - tải miễn phí từ tailieunhanh
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: A multicenter study

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: A multicenter study
12    6    1
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
11    55    1
Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: A large, multicenter, observational study

Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: A large, multicenter, observational study
11    49    1
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
10    47    1
Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data

Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data
11    41    1
Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management
13    86    1
Neutrophil-to-lymphocyte and platelet-tolymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation

Neutrophil-to-lymphocyte and platelet-tolymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation
9    89    0
Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study

Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study
10    44    0
Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: A retrospective study

Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: A retrospective study
12    66    1
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: A randomized controlled trial
13    41    1
Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): Study protocol of a multicentre randomized controlled trial

Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): Study protocol of a multicentre randomized controlled trial
7    1    1
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
11    37    1
CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: A post-hoc analysis of FOWARC trial

CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: A post-hoc analysis of FOWARC trial
12    46    1
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
9    1    1
Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: The ABLATIVE-2 trial—a study protocol

Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: The ABLATIVE-2 trial—a study protocol
12    7    1
Báo cáo y học:

Báo cáo y học: "Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer"
15    42    0
Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: A multicenter, randomized controlled trial (KONCLUDE)

Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: A multicenter, randomized controlled trial (KONCLUDE)
8    44    1
Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): The protocol of a prospective, single-arm, phase II trial

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): The protocol of a prospective, single-arm, phase II trial
9    4    1
Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients

Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients
12    4    1
Analysis of neoadjuvant chemotherapy for breast cancer: A 20-year retrospective analysis of patients of a single institution

Analysis of neoadjuvant chemotherapy for breast cancer: A 20-year retrospective analysis of patients of a single institution
9    7    1